Differentiation between inflammatory myofibroblastic tumor and cholangiocarcinoma manifesting as target appearance on gadoxetic acid-enhanced MRI
- 83 Downloads
To determine the differential features of inflammatory myofibroblastic tumor (IMT) and intrahepatic cholangiocarcinoma (ICC) manifesting as target appearance on gadoxetic acid-enhanced MRI.
Twenty-seven patients with 36 IMTs (1.2–6.0 cm) and 34 patients with 34 ICCs (1.5–6.0 cm) who underwent gadoxetic acid-enhanced MRI were enrolled in this study. Two reviewers evaluated morphology, signal intensity, and enhancement features of tumors on T1-weighted imaging (T1WI), T2-weighted imaging (T2WI), diffusion-weighted imaging (DWI), and gadoxetic acid-enhanced imaging.
As for 32 IMTs with target appearance, IMTs most commonly demonstrated early target appearance characterized by a peripheral hypointense rim on unenhanced T1WI (n = 27, 84.4%), central enhanced area with a hypointense rim on arterial phase (AP) and portal venous phase (PVP) (n = 29, 90.6%), and transitional phase (TP) (n = 28, 87.5%). Meanwhile, most of the ICCs showed homogeneous hypointensity on T1WI (100%), a hyperenhancing rim on AP, late target appearance on TP (n = 32, 94.1%) and HBP (n = 32, 94.1%). Target appearance on DWI appearing as hyperintensity with central hypointense area was seen in 2 IMTs and 32 ICCs. On T2WI, 24 IMTs (n = 24, 75.0%) displayed central iso- and peripheral hyperintensity and 27 ICCs (84.4%) showed layered hyperintensity with either brighter or darker area in center. The remaining six IMTs with no target were observed as cystic appearing nodules (n = 3) or ill-defined hypovascular nodules (n = 2) and fibrotic mass (n = 1).
IMTs often show early target appearance on unenhanced T1WI, and early dynamic phases of gadoxetic acid-enhanced MRI. Target appearance on later phases, such as TP and HBP, and DWI target appearance were commonly in ICCs, but rare in IMTs.
KeywordsMagnetic resonance imaging Liver tumors Inflammatory pseudotumor Cholangiocarcinoma Target appearance
Compliance with ethical standards
Conflict of interest
The authors declared that they have no conflict of interest.
All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.
Informed consent was waived by IRB.
- 1.Yamamoto H, Yamaguchi H, Aishima S, Oda Y, Kohashi K, Oshiro Y, Tsuneyoshi M (2009) Inflammatory myofibroblastic tumor versus IgG4-related sclerosing disease and inflammatory pseudotumor: a comparative clinicopathologic study. Am J Surg Pathol 33:1330–1340. https://doi.org/10.1097/PAS.0b013e3181a5a207 CrossRefPubMedGoogle Scholar
- 2.Pannain VL, Passos JV, Rocha Filho A, Villela-Nogueira C, Caroli-Bottino A (2010) Agressive inflammatory myofibroblastic tumor of the liver with underlying schistosomiasis: a case report. World J Gastroenterol 16:4233–4236. https://doi.org/10.3748/wjg.v16.i33.4233 CrossRefPubMedPubMedCentralGoogle Scholar
- 6.Bae SK, Abiru S, Kamohara Y, Hashimoto S, Otani M, Saeki A, Nagaoka S, Yamasaki K, Komori A, Ito M, Fujioka H, Yatsuhashi H (2015) Hepatic inflammatory pseudotumor associated with xanthogranulomatous cholangitis mimicking cholangiocarcinoma. Inter Med 54:771–775. https://doi.org/10.2169/internalmedicine.54.2623 CrossRefGoogle Scholar
- 10.Elsayes KM, Hooker JC, Agrons MM, Kielar AZ, Tang A, Fowler KJ, Chernyak V, Bashir MR, Kono Y, Do RK, Mitchell DG, Kamaya A, Hecht EM, Sirlin CB (2017) 2017 Version of LI-RADS for CT and MR Imaging: An Update. Radiographics 37:1994–2017. https://doi.org/10.1148/rg.2017170098 CrossRefPubMedGoogle Scholar
- 12.Min JH, Kim YK, Choi SY, Jeong WK, Lee WJ, Ha SY, Ahn S, Ahn HS (2017) Differentiation between cholangiocarcinoma and hepatocellular carcinoma with target sign on diffusion-weighted imaging and hepatobiliary phase gadoxetic acid-enhanced MR imaging: Classification tree analysis applying capsule and septum. Eur J Radiol 92:1–10. https://doi.org/10.1016/j.ejrad.2017.04.008 CrossRefPubMedGoogle Scholar
- 18.Kang TW, Kim SH, Jang KM, Choi D, Choi JY, Park CK (2014) Inflammatory myofibroblastic tumours of the liver: gadoxetic acid-enhanced and diffusion-weighted MRI findings with 18F-FDG PET/CT and clinical significance of regression on follow-up. Clin Radiol 69:509–518. https://doi.org/10.1016/j.crad.2013.12.018 CrossRefPubMedGoogle Scholar
- 20.Hiwatashi A, Kinoshita T, Moritani T, Wang HZ, Shrier DA, Numaguchi Y, Ekholm SE, Westesson PL (2003) Hypointensity on diffusion-weighted MRI of the brain related to T2 shortening and susceptibility effects. AJR Am J Roentgenol 181:1705–1709. https://doi.org/10.2214/ajr.181.6.1811705 CrossRefPubMedGoogle Scholar
- 23.Kim SH, Lee CH, Kim BH, Kim WB, Yeom SK, Kim KA, Park CM (2012) Typical and atypical imaging findings of intrahepatic cholangiocarcinoma using gadolinium ethoxybenzyl diethylenetriamine pentaacetic acid-enhanced magnetic resonance imaging. J Comput Assist Tomogr 36:704–709. https://doi.org/10.1097/RCT.0b013e3182706562 CrossRefPubMedGoogle Scholar